{"schema_version":"secwatch.filing_event.v1","accession":"0000950142-21-002677","form_type":"8-K","ticker":"NRXP","cik":"0001719406","company_name":"NRX Pharmaceuticals, Inc.","filed_at":"2021-08-19T23:59:59+00:00","discovered_at":"2026-05-14T18:04:19.361400+00:00","generated_at":"2026-06-29T08:57:49.436991+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"NRx Pharmaceuticals CFO William Fricker to leave Aug 30; James Brandon named Acting CFO","bullets":["William Fricker to depart as CFO and Treasurer effective August 30, 2021; no disagreements cited.","James Brandon to serve as Comptroller and Acting CFO; Alessandra Daigneault as Acting Treasurer.","Ira Strassberg hired as financial consultant to lead CFO recruitment; previously Deputy CFO of Cantor Fitzgerald.","Fricker will receive a $100,000 annual bonus for completing his employment contract."],"urls":{"canonical":"https://secwatch.observer/filing/0000950142-21-002677","json":"https://secwatch.observer/filing/0000950142-21-002677.json","markdown":"https://secwatch.observer/filing/0000950142-21-002677.md","text":"https://secwatch.observer/filing/0000950142-21-002677.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1719406/000095014221002677/0000950142-21-002677-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1719406/000095014221002677/eh210178862_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T08:57:49.436991+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"489b96a6ad","claim":"James Brandon was appointed as Comptroller and Acting Chief Financial Officer at NRX Pharmaceuticals, Inc..","evidence_excerpt":"James Brandon, who served as Comptroller and Acting CFO for NeuroRx, Inc. since inception through 2020, will resume those duties","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1719406/000095014221002677/0000950142-21-002677-index.htm","confidence":0.92,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Comptroller and Acting Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"53bd3d87df","claim":"Alessandra Daigneault was appointed as Acting Treasurer at NRX Pharmaceuticals, Inc..","evidence_excerpt":"Alessandra Daigneault, the Company’s General Counsel and Corporate Secretary will serve as Acting Treasurer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1719406/000095014221002677/0000950142-21-002677-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Acting Treasurer"}],"fact_type":"executive_change"},{"claim_id":"fd9f3c7010","claim":"William Fricker departed as Chief Financial Officer (CFO) and Treasurer at NRX Pharmaceuticals, Inc..","evidence_excerpt":"announced the upcoming departure of William Fricker, Chief Financial Officer (CFO) and Treasurer. Mr. Fricker’s last day with the Company will be August 30, 2021.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1719406/000095014221002677/0000950142-21-002677-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"departed"},{"label":"Role","value":"Chief Financial Officer (CFO) and Treasurer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}